URINARY IMMATURE TRUNCATED O-GLYCANS CORRELATE WITH GLOMERULAR AND TUBULOINTERSTITIAL SEVERITY OF BIOPSY-PROVEN DIABETIC KIDNEY DISEASE

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

https://storage.unitedwebnetwork.com/files/1099/36b07ed3b768c1457ee63181945408aa.pdf

Abstract Title *

URINARY IMMATURE TRUNCATED O-GLYCANS CORRELATE WITH GLOMERULAR AND TUBULOINTERSTITIAL SEVERITY OF BIOPSY-PROVEN DIABETIC KIDNEY DISEASE

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Yu Tanaka yu.012682228@gmail.com Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science Department of Nephrology, Rheumatology, Endocrinology, and Metabolism Okayama Japan *

Co-author 2

Koki Mise kokims-frz@okayama-u.ac.jp Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science Department of Nephrology, Rheumatology, Endocrinology, and Metabolism Okayama Japan -

Co-author 3

Yasuhiro Onishi oocyst0024@gmail.com Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science Department of Comprehensive Therapy for Chronic Kidney Disease Okayama Japan -

Co-author 4

Katsuyuki Tanabe tanabek@okayama-u.ac.jp Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science Department of Nephrology, Rheumatology, Endocrinology, and Metabolism Okayama Japan -

Co-author 5

Haruhito Uchida hauchida@okayama-u.ac.jp Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science Department of Chronic Kidney Disease and Cardiovascular Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan -

Co-author 6

Jun Wada junwada@okayama-u.ac.jp Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science Department of Nephrology, Rheumatology, Endocrinology, and Metabolism Okayama Japan -

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

Since it has been technically challenging to quantify glycans due to their structural complexity, little is known about the association between changes of glycosylation and the progression of DKD. We previously reported that urinary levels of immature truncated O-glycans, referred to as DKD related O-glycans, strongly predicted renal prognosis in patients with type 2 diabetes (Diabetes Care. 2018;41:1765-1775). However, the association of those O-glycans in urine and blood with the pathological findings of DKD remains elusive.

Methods

We enrolled 36 patients with type 2 diabetes and biopsy-proven DKD in this study. Using serum and urine samples at renal biopsy, we measured the levels of Cy3-labeled glycoproteins binding to 45 lectins with different specificities. Specifically, we analyzed binding signals of DKD related O-glycans to the lectins, e.g. Sialyl-Tn to SNA, Galb4GlcNAc to RCA120, T-antigen to ABA, Jacalin, and ACA, and GalNAca3GalNAc to DBA. The RPS pathologic classification was used to evaluate glomerular and tubulointerstitial lesions in DKD. The relationships of glomerular classes and interstitial fibrosis and tubular atrophy (IFTA) scores with serum and urinary DKD related O-glycan levels were analyzed.

Results

At renal biopsy, 29 patients had macroalbuminuria (81%), and 7 patients showed either normoalbuminuria (11%) or microalbuminuria (8%). The profile of DKD related O-glycans in urine was distinct from that in serum. Among glomerular classes I, IIA, and IIB, urinary DKD related O-glycans gradually increased (p for trend <0.05 for all 6 glycans), while such trend was observed only in RCA120, ABA, Jacalin binding O-glycans in the serum. In contrast, higher urinary levels of T-antigens recognized by ABA, Jacalin, and ACA were significantly associated with higher IFTA scores (P for trend: 0.012, 0.027, and 0.009, respectively), whereas there was no correlation between serum DKD related O-glycans and IFTA scores.

Conclusion

This study discovered that urinary levels of DKD related O-glycans, especially T-antigens, were correlated with the pathological development of early glomerular lesions and tubulointerstitial lesions. Given that such findings were observed in only urinary sample, urinary DKD related O-glycans might reflect the alteration of glycosylation in tissues of DKD.

Kewords